Akebia Therapeutics Inc (AKBA)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Akebia Therapeutics Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.

Akebia Therapeutics develops and commercializes treatments for kidney disease patients. The company markets Vafseo, an oral medicine for anemia in dialysis patients, and Auryxia, which manages phosphorus levels and iron deficiency anemia in chronic kidney disease. Akebia also maintains a pipeline of mid-stage and early-stage programs targeting rare kidney diseases and other conditions.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Akebia Therapeutics Inc stock.

Our verdict on AKBA

Undervalued: intrinsic value $0.97 per share, market price $0.40, margin of safety 58.7% (as of 2026-11-17).

Discounting its cash flows at 6.9% (average of 2 methods) values the shares at $0.97; the price of $0.40 is 59% below that value, and 81% of that value comes from beyond year five.

ETFs with the most weight in AKBA

17 more funds hold it; the full list is part of the paid plan.

More on AKBA

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than AKBA in Drug Manufacturers - Specialty & Generic

Is AKBA undervalued or overvalued?

AKBA is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 6.9% (average of 2 methods) values the shares at $0.97; the price of $0.40 is 59% below that value, and 81% of that value comes from beyond year five.

What is the intrinsic value of AKBA?

$0.97 per share (as of the 2026-11-17 close), against a market price of $0.40. That is a margin of safety of 58.7%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.